Study	Design	Approach	Device	Definition of CAD	Results			
Studies showin	Studies showing an association between CAD (and its severity) and clinical outcomes							
Dewey et al.	Multicenter	136 TF	Sapien	Previous PCI or	CAD is			
2010 ¹	registry	35 TA		CABG	associated with increased			
					30-day and			
					2-year mortality after			
					TAVI			
Mancio et al.	Single-center	87 TF or TSc	CoreValve or	Prior PCI or CABG,	CAD is			
2015 ²	registry	4 TA	Sapien	or stenosis $\geq 50\%$	associated with			
2013	registry	4 IA	Sapien	severity	increased			
				seventy	2-year			
					2-year mortality after			
					TAVI			
Franzone et al.	Multicenter	406 motionts	CareValva		CAD is			
2017 ³	registry	496 patients (TF, TA, and	CoreValve, Sapien or	Prior PCI, CABG or MI, or stenosis	associated with			
2017	registry	TSc)	Symetis	\geq 50% severity of a	increased			
		150)	Symeus	≥30% seventy of a major native				
				coronary vessel or	1-year MACCE after			
				bypass graft	TAVI			
Huczek et al.	Multicenter	741 TF	Balloon- and	Stenosis >70%	CAD is			
2018 ⁴	registry	155 other	self-expandable	severity in	associated with			
2010	registry	routes	prosthesis of first	vessel >1.5 mm	increased			
		Toutes	and second	(50% for the left)	30-day			
			generation	(30% for the fert	mortality after			
			generation	mann)	TAVI			
Ryan et al.	Single-center	402 TF	CoreValve or	Stenosis ≥50%	CAD severity			
2018 ⁵	registry	402 11	Sapien	severity in vessel	(according to			
2010	registry		Suplen	\geq 1.5 mm	SS-II) is			
				<u>_</u> 1.5 mm	associated with			
					increased			
					4-year			
					mortality and			
					MACCE after			
					TAVI			
Guedeney et	Multicenter	708 TF	Balloon- and	Prior MI or	CAD is			
al. 2018 ⁶	registry	700 II 79 other routes	self-expandable	coronary	associated with			
	iogisti y	/ other routes	prosthesis	revascularization, or	adverse 1-year			
			prosulosis	diseased coronary	outcomes			
				vessels at	(VARC-2			
				angiography	efficacy			

Table S1. Overview of studies evaluating the clinical impact of CAD on TAVR recipients.

And the second secon
LetterSingle-center124 TFSapien or SapienStenosis ≥70%CAD sever20157registry96 TAXTseverity or ≥50%(according51 TAO51 TAOFor left main, usingSS-1) ratherQCAFor left main, usingSS-1) ratheritself is20157NNNNSingle-center1053 TFMissingPrior PCI, CABG or20178Multicenter1053 TFMissingNI orregistry217 otherinformationMI, or(according20178registry217 otherinformationMI, or(accordingseverity in majoretalSS-1) ratherinformationistensis >50%SS-1) ratherincreasedinformationminorinformationinformationistensis >50%SS-1) ratherincreasedinformationinformationinformationistensis >50%SS-1) ratherincreasedinformationinformationincreasedincreasedincreasedinformationinformationistensis >50%SS-1) ratherincreased
Image: constraint of the state of the st
Khawaja et al. 20157Single-center registry124 TF 96 TA 51 TAOSapien or Sapien XTStenosis ≥70% severity or ≥50% (according for left main, using QCACAD sever (according itself is associated of increased 1-year mortality at TAVIWitberg et al. 20178Multicenter registry1053 TF 1053 TF registryMissing informationPrior PCI, CABG or severity in major itself is associated of increased 1-year mortality at rAVIWitberg et al. 20178Multicenter registry1053 TF 217 other routesMissing informationPrior PCI, CABG or stenosis >50% stenosis >50% stenosis above increased incr
20157registry96 TA 51 TAoXTseverity or ≥50% for left main, using QCA(according than CAD itself is associated vi increased 1-year mortality at TAVIWitberg et al. 20178Multicenter registry1053 TF 217 other routesMissing informationPrior PCI, CABG or stenosis >50% SS-1) rather (according mortality at rateryWitberg et al. 20178Multicenter registry1053 TF 217 other routesMissing informationPrior PCI, CABG or Stenosis >50% stenosis >50% stenosis >50% itself is associated vi increased increased mortality at rateryKaihara et al.Single-center186 patients,CoreValve,>75% stenosis ofCAD with at CAD with at CAD with at CAD with at
Shi TAOfor left main, using QCASS-1) rate than CAD itself is associated vi increased 1-year mortality at TAVIWitberg et al. 20178Multicenter registry1053 TF 217 other routesMissing informationPrior PCI, CABG or MI, or stenosis >50%CAD sever (according stenosis >50%)Witberg et al. 20178Multicenter registry1053 TF 217 other routesMissing informationPrior PCI, CABG or MI, or stenosis >50%CAD sever (according stenosis >50%)Witberg et al. 20178Multicenter routes1053 TF arteryMissing informationPrior PCI, CABG or MI, or stenosis >50%CAD sever (according stenosis >50%)Witberg et al. 20178Multicenter routes1053 TF arteryMissing informationPrior PCI, CABG or MI, or stenosis >50%CAD sever informationWitberg et al. 20178Multicenter registry1053 TF arteryMissing informationPrior PCI, CABG or itself is associated vi increased increased mortality at arteryCAD sever itself is arteryKaihara et al.Single-center186 patients,CoreValve,>75% stenosis ofCAD with at CAD with at core
Witherg et al. 20178Multicenter registry1053 TF 217 other routesMissing informationPrior PCI, CABG or MI, or stenosis >50% stenosis >50% stenosis >50% itself is associated or increased increased increased informationPrior PCI, CABG or MI, or itself is stenosis >50% itself is itself is associated or increased increased increased informationPrior PCI, CABG or MI, or itself is itself is associated or increased
Vitherg et al.Multicenter1053 TFMissingPrior PCI, CABG orCAD sever20178Multicenter1053 TFMissingPrior PCI, CABG orCAD sever20178registry217 otherinformationMI, or(accordingstenosis >50%SS-1) ratherseverity in majoritself isassociated vincreasedincreasedincreasedattributionInformationMI, or(accordingstenosis >50%SS-1) ratheritself isitself isattributionincreaseditself isattributionincreased
Witherg et al. 20178Multicenter registry1053 TF 217 other
Withberg et al. 20178Multicenter registry1053 TF 217 other routesMissing informationPrior PCI, CABG or MI, or stenosis >50%CAD sever (according stenosis >50%)Withberg et al. 20178Multicenter registry1053 TFMissing informationPrior PCI, CABG or MI, or stenosis >50%CAD sever (according istelf is arteryWithberg et al. 20178Multicenter registry1053 TFMissing informationPrior PCI, CABG or MI, or stenosis >50%CAD sever (according istelf is arteryWithberg et al. 20178Multicenter routes1053 TFMissing informationMI, or severity in major(according istelf is arteryWithberg et al. 20178Multicenter routes1053 TFMissing informationMI, or severity in major(according istelf is arteryWithberg et al. A motality at TAVRNotesNotesNotesNotesWithberg et al. A motality at TAVRNotesNotesNotesWithberg et al. A motality at TAVRNotes
Witberg et al. 20178Multicenter registry1053 TF 217 other routesMissing informationPrior PCI, CABG or MI, or stenosis >50% sS-1) rather severity in major itself is arteryCAD sever (according stenosis >50% itself is arteryWitberg et al. 20178Multicenter registry1053 TF 217 other routesMissing informationPrior PCI, CABG or MI, or (according stenosis >50% itself is arteryCAD sever (according itself is arteryWitberg et al. 20178Multicenter routes1053 TF informationMissing MI, or stenosis >50% itself is arterySS-I) rather itself is arteryKaihara et al.Single-center186 patients,CoreValve,>75% stenosis ofCAD with a
Witberg et al. 20178Multicenter registry1053 TF 217 other routesMissing informationPrior PCI, CABG or MI, or stenosis >50% sS-1) rather severity in major itself is arteryCAD sever (according stenosis >10%) itself is arteryWitberg et al. 20178Multicenter registry1053 TF 217 other routesMissing informationPrior PCI, CABG or MI, or (according stenosis >50%) itself is arteryCAD sever (according istelf is arteryKaihara et al.Single-center186 patients,CoreValve,>75% stenosis ofCAD with a
Image: constraint of the second sec
Witherg et al. 20178Multicenter registry1053 TF 217 other routesMissing informationPrior PCI, CABG or MI, or stenosis >50%CAD sever (according stenosis >50%20178217 other routesinformationMI, or stenosis >50%(according than CAD epicardial coronary inself is artery20178217 other routesinformationMI, or severity in major(according than CAD epicardial coronary increased mortality at TAVRKaihara et al.Single-center186 patients,CoreValve,>75% stenosis ofCAD with at
20178registry217 other routesinformationMI, or stenosis >50%(according SS-I) rather severity in major20178registry217 other routesinformationMI, or stenosis >50%(according SS-I) rather severity in major20178routesroutesroutesinformationMI, or stenosis >50%(according stenosis >50%20178routesroutesroutesinformationinformationitself is artery20178routesroutesroutesincreased mortality at TAVR20179Single-center186 patients,CoreValve,>75% stenosis ofCAD with at can be stenosis of
routes routes stenosis >50% SS-I) rather severity in major than CAD epicardial coronary itself is artery associated wincreased mortality at TAVR Kaihara et al. Single-center 186 patients, CoreValve, >75% stenosis of CAD with at
Kaihara et al. Single-center 186 patients, CoreValve, >75% stenosis of CAD with a context of
Kaihara et al. Single-center 186 patients, CoreValve, >75% stenosis of CAD with a
Kaihara et al. Single-center 186 patients, CoreValve, >75% stenosis of CAD with a
Kaihara et al. Single-center 186 patients, CoreValve, >75% stenosis of CAD with a
Kaihara et al. Single-center 186 patients, CoreValve, >75% stenosis of CAD with a
Kaihara et al. Single-center 186 patients, CoreValve, >75% stenosis of CAD with a
Kaihara et al. Single-center 186 patients, CoreValve, >75% stenosis of CAD with a
2021 ⁹ registry missing Evolut R, Sapien ≥1 major branch or LM or LAI
information XT, Sapien 3 50% stenosis only proximal
regarding in the LM lesion is a
access route strong
independen
predictor of
mid-term
MACCEs a
all-cause
mortality in
patients wit
severe AS
treated with
TAVI.
Studies showing no association between CAD (and its severity) and clinical outcomes
Masson et al. Single-center 93 TF Cribier-Edwards Prior Lack of
2010 ¹⁰ registry 43 TA or Sapien revascularization or association
any coronary between the
stenosis $\ge 50\%$ extent of C.
severity (according

					DMJS) and
					1-year
					mortality
					post-TAVI
Gautier et al.	Single-center	TF, TA or TSc	CoreValve or	Stenosis ≥ 70%	CAD does not
2011 ¹¹	registry	(144 patients)	Sapien	severity or $\geq 50\%$	associate with
		()		for left main, using	1-year
				QCA	mortality after
				QUI	TAVI
Abdel-Wahab	Multicenter	1209 TF	CoreValve or	Prior PCI or CABG,	CAD is
et al. 2012 ¹²	registry	1207 H 122 TA 10	Sapien	or stenosis $\geq 50\%$	associated with
ct al. 2012	registry	TAo	Sapien	severity	increased
		41 TSc		seventy	
		41 150			in-hospital
					mortality after
					TAVR by
					univariate
					analysis, but
					not by
					multivariate
					analysis
Ussia et al.	Multicenter	595 TF	CoreValve	Prior PCI or CABG	CAD does not
2013 ¹³	registry	64 TA			associate with
					increased
					1-year
					mortality or
					MACCE after
					TAVI
Gasparetto et	Single-center	128 TF	CoreValve,	Prior PCI or CABG	CAD is not
al. 2013 ¹⁴	registry	58 TA	Sapien or Sapien	or stenosis > 50%	associated with
		5 TSc	XT	severity	1-year
					combined
					efficacy
					endpoint after
					TAVI
Codner et al.	Single-center	112 TF	CoreValve or	Missing	CAD is
2013 ¹⁵	registry	27 TA	Sapien	information	associated with
		1 TAo			increased
		13 TSc			2-year
					mortality after
					TAVI by
					univariate
					analysis, but
					no longer by
					multivariate
					munuvariate

					analysis
Linke et al.	Multicenter	880 TF	CoreValve	Missing	CAD is not
2014 ¹⁶	registry	21 Tao		information	associated with
		95 TSc			increased
					1-year
					mortality after
					TAVRI
Stefanini et al.	Single-center	348 TF	CoreValve,	Stenosis ≥50%	CAD severity
2014 ¹⁷	registry	92 TA	Sapien or	severity in vessel	(according to
		5 TSc	Symetis	≥1.5 mm in	SS-I) is
				diameter	associated with
					increased
					1-year
					MACCE after
					TAVI by
					univariate
					analysis, but
					not by
					multivariate
					analysis
Snow et al.	Multicenter	1750 TF	CoreValve,	Stenosis >50%	CAD is
2015 ¹⁸	registry	838 other	Sapien or Sapien	severity in major	associated with
		routes	XT	epicardial coronary	increased
				vessel	4-year
					mortality after
					TAVI by
					univariate
					analysis, but
					not by
					multivariate
					analysis
Schymik et al.	Multicenter	1685 TF	Sapien XT	Missing	CAD is
2015 ¹⁹	registry	894 TA		information	associated with
		109 Tao/TSc			increased
					1-year
					mortality after
					TAVI by
					univariate
					analysis, but
					not by
					multivariate
					analysis
Paradis et al.	Multicenter	182 TF	Sapien, Sapien	Stenosis ≥50%	Neither CAD
2017 ²⁰	registry	195 TA	XT or Sapien 3	severity by QCA	nor its severity

				estimation in	according to
				vessels ≥1.5 mm	SS-I is
					associated with
					MACCE
					occurrence
					after TAVI
Puymirat et al.	Multicenter	2600 TF	CoreValve and	Stenosis of >50%	Neither CAD
2017 ²¹	registry	506 TA	Sapien	diameter in major	nor extent of
2017	Patients with	190 TSc	Sapien	epicardial coronary	CAD is
	prior CABG	127 Other		vessel	associated with
	were excluded	routes		103501	increased
	were excluded	Toutes			3-year
					mortality after
					TAVI
Millan-Iturbe	Single-center	884 TF	Centera,	At least one	CAD is not
et al. 2017 ²²	registry	12 TA	CoreValve,	stenosis >70%	associated
et al. 2017	Tegistry	12 IA 1 TAo	Evolut R, Lotus,	severity (50% for	with increased
		47 TSc	Portico, Sapien	the left main)	long-term
		47 150		the feft main)	
			3, Symetis		mortality after TAVI
Channalah: 4		C41 TE	Conton	Store -:- >500/	
Shamekhi et	Single-center	641 TF	Centera,	Stenosis ≥50%	CAD severity
al. 2017 ²³	registry	8 TAo	CoreValve,	severity in vessel	(according to
		3 TA	Direct Flow,	≥1.5 mm	SS-I) is
		14 TSc	Evolut R,		associated with
			Engager, Lotus,		increased
			Sapien XT,		3-year
			Sapien 3,		mortality after
			Symetis		TAVI by
					univariate
					analysis, but
					not by
					multivariate
	C' 1	225 755			analysis
Lopez-Otero et	Single-center	335 TF	CoreValve	Stenosis ≥50%	Neither CAD
al. 2019 ²⁴	registry	14 TA		severity in vessel	nor its severity
				\geq 1.5 mm in	according to
				diameter	SS-I is
					associated with
					MACCE
					occurrence
					after TAVI
Chodòr et al.	Single-center	109 TF	CoreValve,	prior PCI or CABG,	CAD is not
2019 ²⁵	registry	33 other routes	Evolut R, Sapien	history of	associated with
			XT, Sapien 3	myocardial	30-day and

				infarction, stenosis	1-year
				of at least one	mortality after
				coronary artery at	TAVI
				\geq 50% of its	
				diameter	
Elbaz et al.	Single-center	753 TF	CoreValve,	Stenosis >70%	Neither the
2020 ²⁶	registry	134 other	Evolut R, Sapien	obstruction in any	number of
		routes	XT, Sapien 3	of the left anterior	disease vessels
				descending artery,	nor PCI before
				circumflex artery,	TAVI is
				or right coronary	significantly
				artery, or >50%	associated with
				obstruction in the	either 30-day
				left main coronary	or 1-year
				artery. Prior CABG	mortality
				excluded	
Studies show	ving no associati	on between th	e stable CAD and	clinical outcomes e	except for
<u>acute corona</u>	<u>ry syndrome</u>				
Saia et al.	Single-center	413 TF	CoreValve,	presence of at least	Neither CAD
2019 ²⁷	registry	81 TA	Evolut R, Sapien	one stenosis >70%	nor its severity
		31 TAo	XT, Sapien 3,	at visual estimation	is associated
		15 TSc	Symetis, Portico,	(>50% for the left	with MACCE
			Jena	main coronary	occurrence
				artery) of an	after TAVI
				epicardial vessel	except for
				with diameter ≥ 2	patients
				mm OR previous	presenting with
				coronary	acute coronary
				revascularization	syndrome

CABG, Coronary artery bypass graft; CAD, Coronary artery disease; MACCE, Major adverse cardiovascular and cerebrovascular event; MI, Myocardial infarction; PCI, Percutaneous coronary intervention; QCA, Quantitative coronary angiography; TAVI, Trans-catheter aortic valve implantation; SS, Syntax score; TA, Trans-apical; Tao, Trans-aortic; TF, Trans-femoral; TSc, Trans-subclavian.

Table S2. Overview of studies evaluating the clinical impact of PCI pre-TAVI.

Study	Design	Population	Approach	Device	Results
Wenaweser et	Single-center	59 TAVR+PCI	197 TF	CoreValve or	No differences
al. 2011 ²⁸	registry	197 isolated	55 TA	Sapien	in 2-year
		TAVR	4 TSc		all-cause
					mortality

					NT 1'00
Abdel-Wahab et al. 2012 ²⁹	Single-center registry	55 TAVR+PCI 70 isolated TAVR	124 TF 1 TSc	CoreValve	No differences in 3-year all-cause mortality
Codner et al. 2013 ¹⁵	Single-center registry	36 TAVR+PCI 117 isolated TAVR	112 TF 27 TA 1 Tao 13 TSc	CoreValve or Sapien	No differences in 2-year all-cause mortality
Abramowitz et al. 2014 ³⁰	Single-center registry	61 TAVR+PCI 83 isolated TAVR (with CAD) 105 isolated TAVR (without CAD)	TF or TSc	CoreValve or Sapien	No differences in 3-year all-cause mortality
Khawaja et al. 2015 ⁷	Single-center registry	25 TAVR+PCI 68 isolated TAVR (with CAD)	124 TF 96 TA 51 TAo	Sapien or Sapien XT	No differences in 1-year all-cause mortality
Snow et al. 2015 ¹⁸	Multicenter registry	2005 TAVR without previous PCI 363 TAVR with historical PCI 169 TAVR with hybrid PCI	TF or other routes	CoreValve, Sapien or Sapien XT	No differences in 5-year all-cause mortality
Huczek et al. 2016 ⁴	Multicenter registry	169 TAVR+PCI 293 isolated TAVR (with CAD) 434 isolated TAVR (without CAD)	741 TF 155 other routes	Balloon- and self-expandable prosthesis of first and second generation	No differences in 30-day mortality
Chakravarty et al. 2016 ³¹	Multicenter registry	128 TAVR+LM PCI 128 isolated TAVR	149 TF 38 TA 12 TAo 5 TSc	CoreValve, Direct Flow, or Edwards	No differences in 1-year all-cause mortality
Millan-Iturbe et al. 2017 ²²	Single-center registry	136 TAVR+PCI 88 isolated	884 TF 12 TA 1 TAo	Centera, CoreValve, Evolut R, Lotus, Portico, Sapien 3,	No differences in 9-year all-cause

		TAVR (with	47 TSc	Sumatia	montality
			4/150	Symetis	mortality
		CAD)			
		720 isolated			
		TAVR (without			
		CAD)			
Guedeney et al.	Multicenter	459 isolated	708 TF	Balloon- and	Patients with
20186	registry	TAVI (without	79 other	self-expandable	recent PCI had
		CAD)	routes	prosthesis	increased risk of
		241 isolated			all-cause death
		TAVI (cad			and stroke
		patients			compared with
		without recent			patients without
		PCI)			CAD.
		81 TAVI + PCI			
Faroux et al.	Multicenter	1197 TAVI +	974 TF	Balloon-expandable,	After a median
2020 ³²	registry	PCI before	135 TA	self-expanding and	follow-up of 2
			24 TAo	mechanically	years
			25 TSc	expandable	post-TAVI, 100
			39 Tcr		(8.4%) patients
					presented an
					ACS and 105
					(8,8%) had
					cardiovascular
					death
Elbaz et al.	Single-center	444 TAVI +	753 TF	CoreValve, Evolut	PCI before
2020 ²⁶	registry	PCI before	134 other	R, Sapien XT,	TAVI is not
		444 isolated	routes	Sapien 3	significantly
		TAVI (with			associated with
		CAD)			either 30-day or
					1-year mortality
Kaihara et al.	Single-center	108 Isolated	186 patients,	CoreValve, Evolut	PCI before
2021 ⁹	registry	TAVI (without	missing	R, Sapien XT,	TAVI did not
		CAD)	information	Sapien 3	influence the
		29 TAVI + PCI	regart access		outcomes.
		49 isolated	route		
		TAVI (with			
		CAD)			
		,			

CAD, coronary artery disease; LM, left main stem; PCI, percutaneous coronary intervention; TA, trans-apical; Tao, trans-aortic; TAVI, transcatheter aortic valve implantation; TCr, transcarotid; TF, trans-femoral; TSc, trans-subclavian.

REFERENCE

1. Dewey TM, Brown DL, Herbert MA et al. Effect of concomitant coronary artery disease on procedural and late outcomes of transcatheter aortic valve implantation. Ann Thorac Surg 2010;89:758-67. [PMID: 20172123 doi: 10.1016/j.athoracsur.2009.12.033]

2. Mancio J, Fontes-Carvalho R, Oliveira, et al. Coronary Artery Disease and Symptomatic Severe Aortic Valve Stenosis: Clinical Outcomes after Transcatheter Aortic Valve Implantation. Front Cardiovasc Med 2015;2:18. [PMID: 26664890 doi: 10.3389/fcvm.2015.00018]

3. Franzone A, Stortecky S, Räber L et al. Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A study of ageand gender-matched cohorts. Int J Cardiol 2017;243:150-5. [PMID: 28536005 doi: 10.1016/j.ijcard.2017.05.071]

4. Huczek Z, Zbroński K, Grodecki K et al. Concomitant coronary artery disease and its management in patients referred to transcatheter aortic valve implantation: Insights from the POL-TAVI Registry. Catheter Cardiovasc Interv 2018;91:115-23. [PMID: 28843025 doi: 10.1002/ccd.27251]

5. Ryan N, Nombela-Franco L, Jiménez-Quevedo P et al. The Value of the SYNTAX Score II in Predicting Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation. Rev Esp Cardiol 2018;71:628-37. [PMID: 29191780 doi: 10.1016/j.rec.2017.10.014]

6. Guedeney P, Tchétché D, Petronio AS et al. Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry. Catheter Cardiovasc Inter 2017;93:1124-31.[PMID:30511802 doi: 10.1002/ccd.28012]

7. Khawaja MZ, Asrress KN, Haran H et al. The effect of coronary artery disease defined by quantitative coronary angiography and SYNTAX score upon outcome after transcatheter aortic valve implantation (TAVI) using the Edwards bioprosthesis. EuroIntervention 2015;11:450-5.[PMID: 24832041 doi: 10.4244/EIJY14M05 09]

8. Witberg G, Regev E, Chen S, et al. The prognostic effects of coronary disease severity and completeness of revascularization on mortality in patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2017;10(14):1428–35. [PMID: 28728656 doi: 10.1016/j.jcin.2017.04.035]

9. Kaihara T, Higuma T, Izumo M et al. Influence of coronary artery disease and percutaneous coronary intervention on mid-term outcomes in patients with aortic valve stenosis treated with transcatheter aortic valve implantation. Clin Cardiol. 2021 May 25. [PMID: 34033124 doi: 10.1002/clc.23655]

10. Masson JB, Lee M, Boone RH et al. Impact of coronary artery disease on outcomes after transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2010;76:165-73. [PMID: 20665855 doi: 10.1002/ccd.22501]

11. Gautier M, Pepin M, Himbert D et al. Impact of coronary artery disease on indications for transcatheter aortic valve implantation and on procedural outcomes. EuroIntervention 2011;7:549-55. [PMID: 21930458 doi: 10.4244/EIJV7I5A90]

12. Abdel-Wahab M, Zahn R, Horack M et al. Transcatheter aortic valve implantation in patients with and without concomitant coronary artery disease: comparison of characteristics and early outcome in the German multicenter TAVI registry. Clin Res Cardiol 2012;101:973-81. [PMID: 22772776 doi: 10.1007/s00392-012-0486-5]

13. Ussia GP, Barbanti M, Colombo A et al. Impact of coronary artery disease in elderly patients undergoing transcatheter aortic valve implantation: insight from the Italian CoreValve Registry. Int J Cardiol 2013;167:943-50. [PMID: 22459391 doi: 10.1016/j.ijcard.2012.03.089]

14. Gasparetto V, Fraccaro C, Tarantini G et al. Safety and effectiveness of a selective strategy for coronary artery revascularization before transcatheter aortic valve implantation. Catheter Cardiovasc Inter 2013;81:376-383. [PMID: 22461314 doi: 10.1002/ccd.24434]

15. Codner P, Assali A, Dvir D et al. Two-year outcomes for patients with severe symptomatic aortic stenosis treated with transcatheter aortic valve implantation. Am J Cardiol 2013;111:1330-6. [PMID: 23415022 doi: 10.1016/j.amjcard.2013.01.275]

16. Linke A, Wenaweser P, Gerckens U et al. Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study. Eur Heart J 2014;35:2672-84. [PMID: 24682842 doi: 10.1093/eurheartj/ehu162]

17. Stefanini GG, Stortecky S, Cao D et al. Coronary artery disease severity and aortic stenosis: clinical outcomes according to SYNTAX score in patients undergoing transcatheter aortic valve implantation. Eur Heart J 2014 35;2530-40. [PMID: 24682843 doi: 10.1093/eurheartj/ehu074]

18. Snow TM, Ludman P, Banya W et al. Management of concomitant coronary artery disease in patients undergoing transcatheter aortic valve implantation: the United Kingdom TAVI Registry. Int J Cardiol 2015;199:253-60. [PMID: 26209948 doi: 10.1016/j.ijcard.2015.06.166]

19. Schymik G, Lefèvre T, Bartorelli AL et al. European experience with the second-generation Edwards SAPIEN XT transcatheter heart valve in patients with severe aortic stenosis: 1-year outcomes from the SOURCE XT Registry. J Am Coll Cardiol Cardiovasc Interv 2015;8:657-69. [PMID: 25946437 doi: 10.1016/j.jcin.2014.10.026]

20. Paradis JM, White JM, Généreux P et al. Impact of Coronary Artery Disease Severity Assessed With the SYNTAX Score on Outcomes Following Transcatheter Aortic Valve Replacement. J Am Heart Assoc. 2017;6. Pii: e005070. [PMID: 28219920 doi: 10.1161/JAHA.116.005070]

21. Puymirat E, Didier R, Eltchaninoff H et al. Impact of coronary artery disease in patients undergoing transcatheter aortic valve replacement: Insights from the FRANCE-2 registry. Clin Cardiol 2017;40:1316-22. [PMID: 29247516 doi: 10.1002/clc.22830]

22. Millan-Iturbe O, Sawaya FJ, Lønborg J et al. Coronary artery disease, revascularization, and clinical outcomes in transcatheter aortic valve replacement: Real-world results from the East Denmark Heart Registry. Catheter Cardiovasc Interv 2018;92:818-26. [PMID: 29214718 doi: 10.1002/ccd.27440]

23. Shamekhi J, Stundl A, Weber M et al. Impact of coronary artery disease in patients undergoing transfermoral transcatheter aortic valve implantation. Int J Cardiol 2017;245:215-21. [PMID: 28789844 doi: 10.1016/j.ijcard.2017.07.082]

24. López Otero D, Ávila-Carrillo A, González Ferreiro R, et al. Impact of Coronary Revascularization in Patients Who Underwent Transcatheter Aortic Valve Implantation. Am J Cardiol. 2019 Mar 15;123(6):948-955. [PMID: 30598242 doi: 10.1016/j.amjcard.2018.12.007]

25. Chodór P, Wilczek K, Włoch Ł, et al. Impact of coronary artery disease on outcomes of severe aortic stenosis treatment with transcatheter aortic valve implantation. Postepy Kardiol Interwencyjnej. 2019;15(2):167-175. [PMID: 31497049 doi: 10.5114/aic.2019.84394]

26. Elbaz GG, Henning KA, Qiu F, et al. Impact of Coronary Artery Severity and Revascularization Prior to Transcatheter Aortic Valve Implantation. Am J Cardiol. 2020 Mar 15;125(6):924-930. [PMID: 31954508 doi: 10.1016/j.amjcard.2019.12.021]

27. Saia F, Palmerini T, Compagnone M, et al. Coronary artery disease and reasonably incomplete coronary revascularization in high-risk patients undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2020 Jan;95(1):19-27. [PMID: 30916884 doi: 10.1002/ccd.28211]

28. Wenaweser P, Pilgrim T, Guerios E et al. Impact of coronary artery disease and percutaneous coronary intervention on outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. EuroIntervention 2011;7:541-8. [PMID: 21930453 doi: 10.4244/EIJV7I5A89]

29. Abdel-Wahab M, Mostafa AE et al. Comparison of outcomes in patients having isolated transcatheter aortic valve implantation versus combined with preprocedural percutaneous coronary intervention. Am J Cardiol 2012;109:581-6. [PMID: 22133754 doi: 10.1016/j.amjcard.2011.09.053]

30. Abramowitz Y, Banai S, Katz G et al. Comparison of early and late outcomes of TAVI alone compared to TAVI plus PCI in aortic stenosis patients with and without

coronary artery disease. Catheter Cardiovasc Interv 2014;83:349-54. [PMID: 24532332 doi: 10.1002/ccd.25233]

31. Chakravarty T, Sharma R, Abramowitz Y et al. Outcomes in Patients With Transcatheter Aortic Valve Replacement and Left Main Stenting: The TAVR-LM Registry. J Am Coll Cardiol 2016;67:951-60. [PMID: 26916485 doi: 10.1016/j.jacc.2015.10.103]

32. Faroux L, Campelo-Parada F, Munoz-Garcia E et al. Procedural Characteristics and Late Outcomes of Percutaneous Coronary Intervention in the Workup Pre-TAVR. JACC Cardiovasc Interv. 2020 Nov 23;13(22):2601-2613. [PMID: 33069647 doi: 10.1016/j.jcin.2020.07.009]